Kisqali (ribociclib) administration does not typically require special preparation or additional medications that would complicate its use from a payer's health technology assessment perspective. The drug is an oral tablet [1].
What are the key considerations for Kisqali administration?
Kisqali is taken orally, usually once a day, for 21 consecutive days, followed by 7 days off [2]. It is important to take the medication at approximately the same time each day [2]. If a dose is missed, patients should take it as soon as they remember, unless it is less than 48 hours until the next scheduled dose, in which case they should skip the missed dose and continue with their regular dosing schedule [2]. Patients should not take two doses at the same time to make up for a missed dose [2].
What side effects might influence payer assessments of Kisqali?
Payer assessments often consider the potential side effects of a drug, as these can impact patient adherence, the need for supportive care, and overall healthcare costs. Common side effects of Kisqali include nausea, fatigue, diarrhea, vomiting, hair loss, and decreased appetite [3]. More serious side effects can include liver problems, low white blood cell counts, and QT prolongation [3].
How does Kisqali's administration compare to other CDK4/6 inhibitors?
Kisqali is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Other drugs in this class, such as palbociclib (Ibrance) and abemaciclib (Verzenio), are also oral medications. Their administration schedules and common side effect profiles share similarities, though specific differences in efficacy, safety, and dosing frequency exist between these agents [4][5].
When do patents for Kisqali expire?
Information on patent expiry for Kisqali (ribociclib) can be found through resources like DrugPatentWatch.com [6]. Patent expirations are a critical factor for payers as they signal potential market entry for generics or biosimilars, which could lead to cost savings.
What is the cost of Kisqali?
The cost of Kisqali can vary significantly depending on insurance coverage, geographic location, and pharmacy. Patients and payers often consult drug pricing databases and manufacturer resources for the most current pricing information.
What clinical data supports Kisqali's use?
Kisqali has demonstrated significant efficacy in clinical trials, particularly when used in combination with endocrine therapy for certain types of breast cancer. Key trials, such as MONALEESA-7, have shown improvements in progression-free survival and overall survival [7].
What regulatory approvals does Kisqali have?
Kisqali is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications, primarily in combination with endocrine therapy for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer [2][8].
Are there patient assistance programs for Kisqali?
Manufacturers often offer patient assistance programs to help eligible patients afford their medications. These programs can reduce out-of-pocket costs for individuals facing financial barriers to treatment.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209521s025lbl.pdf
[2] https://www.kisqali.com/
[3] https://www.mayoclinic.org/drugs-supplements/ribociclib-oral-route/side-effects/drh-20072409
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1605823
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094756/
[6] https://drugpatentwatch.com/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa1809809
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali